Global Pharmaceutical Giants Fast Track US Investment Amid Proposed Import Tariffs
Global drugmakers are accelerating US investments and factory expansions as the Trump administration considers a 100 percent tariff on imported medicines.
Insights:
The Trump administration, led by President Donald Trump donald trump, is currently considering a policy proposal to impose a 100 percent tariff on imported branded and patented medicines. This proposal, which remains under discussion, has triggered a wave of operational changes across the global healthcare sector. In response to the potential trade barriers, pharmaceutical and biotechnology companies are fast-tracking multi-billion-dollar investments in the US 
USto secure exemptions or minimize financial penalties. Enforcement of these proposed pharmaceutical-targeted tariffs is reported to be delayed for companies that commit to expanding their domestic manufacturing footprints, prompting firms to fast-track projects, cut prices, and pursue direct-to-consumer sales.
USto secure exemptions or minimize financial penalties. Enforcement of these proposed pharmaceutical-targeted tariffs is reported to be delayed for companies that commit to expanding their domestic manufacturing footprints, prompting firms to fast-track projects, cut prices, and pursue direct-to-consumer sales.On September 30, Pfizer Inc. reached a landmark agreement with Donald Trumpto invest $70 billion in research and development and domestic manufacturing. As part of this deal, the company received a three-year grace period exempting its products from the pharmaceutical-targeted tariffs. Similarly, AstraZeneca PLC , which operates across GB 
GBand SE 
SE, is reported to have secured multi-year tariff exemptions through pricing deals and commitments to the TrumpRx.gov platform. AstraZeneca PLCplans to invest $50 billion in USmanufacturing by 2030, which includes funding for a new drug substance facility in Virginia. The company has already initiated technology transfers and is managing inventory levels in 2025 to mitigate any immediate tariff impact.
GBand SE SE, is reported to have secured multi-year tariff exemptions through pricing deals and commitments to the TrumpRx.gov platform. AstraZeneca PLCplans to invest $50 billion in USmanufacturing by 2030, which includes funding for a new drug substance facility in Virginia. The company has already initiated technology transfers and is managing inventory levels in 2025 to mitigate any immediate tariff impact.
